APLS Stock Overview A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Apellis Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Apellis Pharmaceuticals Historical stock prices Current Share Price US$30.20 52 Week High US$71.90 52 Week Low US$24.34 Beta 0.95 1 Month Change -12.79% 3 Month Change 0.73% 1 Year Change -55.67% 3 Year Change -35.91% 5 Year Change -28.59% Change since IPO 115.25%
Recent News & Updates
Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) Jan 28
Co-Founder recently sold US$412k worth of stock Jan 24
Co-Founder notifies of intention to sell stock Jan 23
Apellis Pharmaceuticals, Inc. Announces Executive Changes Jan 14
New minor risk - Insider selling Jan 12
Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors Jan 10 See more updates
Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA) Jan 28
Co-Founder recently sold US$412k worth of stock Jan 24
Co-Founder notifies of intention to sell stock Jan 23
Apellis Pharmaceuticals, Inc. Announces Executive Changes Jan 14
New minor risk - Insider selling Jan 12
Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors Jan 10
Apellis: Saved By The October Data Dec 25
There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise Dec 15
Consensus EPS estimates fall by 24% Nov 12
Price target decreased by 18% to US$51.79 Nov 06
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 06
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week Oct 27
Price target decreased by 7.0% to US$63.11 Oct 25
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt? Oct 18
Forecast breakeven date pushed back to 2026 Oct 14
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion Oct 01
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Sep 27
Apellis: Rare Kidney Disease Data Leads To Possible First To Market Aug 09
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
Price target decreased by 7.6% to US$69.12 Aug 04
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
Consensus EPS estimates fall by 11% Jul 28
Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt? Jul 12
Independent Director notifies of intention to sell stock Jun 23
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year May 30
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress May 25
Consensus EPS estimates fall by 17% May 16
Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks May 14
Co-Founder & Chief Scientific Officer notifies of intention to sell stock May 10
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year May 09
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 08
Consensus EPS estimates fall by 18% Apr 30
Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency Apr 27
Consensus EPS estimates upgraded to US$0.98 loss Apr 19
Consensus EPS estimates upgraded to US$1.00 loss Apr 17
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Apr 10
Independent Director notifies of intention to sell stock Mar 21
Chief Technical Operations Officer recently sold US$646k worth of stock Mar 15
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024 Mar 11
Consensus EPS estimates fall by 13%, revenue upgraded Mar 05
Co-Founder notifies of intention to sell stock Mar 04
New minor risk - Financial position Feb 28
Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain Feb 16
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application Jan 26
Co-Founder notifies of intention to sell stock Jan 24
Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer Jan 23
Co-Founder recently sold US$525k worth of stock Jan 18
Price target increased by 9.0% to US$71.44 Jan 11
Price target decreased by 9.6% to US$66.69 Dec 15
Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union Dec 15
Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI Dec 11
CFO & Treasurer exercised options and sold US$633k worth of stock Dec 04
Insufficient new directors Nov 29 Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Nov 02
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G
Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration Oct 05
Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023 Sep 26
Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit Sep 22
Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI Aug 31
Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI Aug 30
Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection) Aug 23
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Aug 16
Co-Founder & Chief Scientific Officer notifies of intention to sell stock Aug 10
Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc Aug 03
No longer forecast to breakeven Aug 01
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 31 Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy Jul 30
Price target decreased by 9.8% to US$93.23 Jul 21
With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For Jul 19
New minor risk - Share price stability Jul 18
General Counsel notifies of intention to sell stock Jul 06
Chief People Officer notifies of intention to sell stock Jun 05
Co-Founder notifies of intention to sell stock May 20
Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week May 13
Consensus revenue estimates increase by 57%, EPS downgraded May 11
Price target increased by 12% to US$100 May 07
Chief Commercial Officer notifies of intention to sell stock May 06
Insufficient new directors May 01
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way? Apr 18
Chief Commercial Officer notifies of intention to sell stock Apr 06
Co-Founder & Director notifies of intention to sell stock Mar 20
Chief Commercial Officer notifies of intention to sell stock Mar 09
Co-Founder exercised options to buy US$6.5m worth of stock. Mar 06
Co-Founder & Director exercised options and sold US$62k worth of stock Feb 23
Price target increased by 13% to US$85.06 Feb 21
FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA) Feb 18
Co-Founder notifies of intention to sell stock Feb 05
Co-Founder & Director notifies of intention to sell stock Jan 22 Shareholder Returns APLS US Biotechs US Market 7D -0.6% 1.3% 0.2% 1Y -55.7% 0.9% 22.0%
See full shareholder returns
Return vs Industry: APLS underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: APLS underperformed the US Market which returned 22.4% over the past year.
Price Volatility Is APLS's price volatile compared to industry and market? APLS volatility APLS Average Weekly Movement 8.8% Biotechs Industry Average Movement 11.4% Market Average Movement 6.1% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: APLS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: APLS's weekly volatility (9%) has been stable over the past year.
About the Company Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
Show more Apellis Pharmaceuticals, Inc. Fundamentals Summary How do Apellis Pharmaceuticals's earnings and revenue compare to its market cap? APLS fundamental statistics Market cap US$3.78b Earnings (TTM ) -US$250.10m Revenue (TTM ) US$715.22m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) APLS income statement (TTM ) Revenue US$715.22m Cost of Revenue US$417.28m Gross Profit US$297.94m Other Expenses US$548.04m Earnings -US$250.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.01 Gross Margin 41.66% Net Profit Margin -34.97% Debt/Equity Ratio 190.7%
How did APLS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 08:28 End of Day Share Price 2025/02/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Michael Ulz Baird Ishan Majumdar Baptista Research
Show 31 more analysts 
